EUVIMEDEUVIMED entdecken
Crossref

Assessment of Serum Cystatin C Level and Neuroprotection Under Levetiracetam Monotherapy in Patients with Epilepsy

Fatma ŞİMŞEK, Seda AŞKIN

New Trends in Medicine Sciences · 2022

DOI: 10.56766/ntms.1108819 ↗

Kurz gefasst

Fachartikel in der Zeitschrift New Trends in Medicine Sciences, 2022. Verfasst von Fatma ŞİMŞEK und 1 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Cystatin C is a cysteine protease inhibitor that has been shown to have antiviral, antibacterial and neuroprotective efficacy. The aim of this study is to assess the effect of levetiracetam monotherapy on serum cystatin C levels and the neuroprotective efficacy thereof in patients with epilepsy. Material and Methods: 30 patients, who were diagnosed with epilepsy for the first time and subsequently started on levetiracetam monotherapy, were included in the study as the study group, whereas 30 healthy volunteers were included in the study as the control group. Serum cystatin C and creatinine levels of patients were measured twice, once before they were started on the levetiracetam treatment and once after the completion of six months of treatment levetiracetam, whereas the serum cystatin C and creatinine levels of the healthy control subjects were measured once.

Results

Both the pre-treatment and post-treatment creatinine levels of epilepsy patients were found to be statistically significantly higher compared to the creatinine levels of the healthy control subjects. The pre-treatment and post-treatment serum cystatin C levels of epilepsy patients were found to be lower compared to the serum cystatin C levels of the healthy control subjects, albeit not statistically significantly. Additionally, serum cystatin C levels of epilepsy patients were found to have increased after the completion of the levetiracetam treatment, even though not statistically significantly.

Conclusion

The increase observed in the cystatin C levels, which is a neuroprotective agent, in epilepsy patients following the completion of the levetiracetam treatment indicates that levetiracetam has neuroprotective activity.

Zitieren

APA

ŞİMŞEK, F., & AŞKIN, S. (2022). Assessment of Serum Cystatin C Level and Neuroprotection Under Levetiracetam Monotherapy in Patients with Epilepsy. New Trends in Medicine Sciences. https://doi.org/10.56766/ntms.1108819

Vancouver

ŞİMŞEK F, AŞKIN S. Assessment of Serum Cystatin C Level and Neuroprotection Under Levetiracetam Monotherapy in Patients with Epilepsy. New Trends in Medicine Sciences. 2022. doi:10.56766/ntms.1108819

BibTeX
@article{MEK2022,
  author = {ŞİMŞEK, Fatma and AŞKIN, Seda},
  title = {Assessment of Serum Cystatin C Level and Neuroprotection Under Levetiracetam Monotherapy in Patients with Epilepsy},
  journal = {New Trends in Medicine Sciences},
  year = {2022},
  doi = {10.56766/ntms.1108819}
}
Kostenlos starten →